Treatment of latent tuberculosis infection in incarcerated people: a systematic review.

[1]  M. Di Paolo,et al.  Not Only COVID-19: Prevalence and Management of Latent Mycobacterium Tuberculosis Infection in Three Penitentiary Facilities in Southern Italy , 2022, Healthcare.

[2]  S. Kerr,et al.  Prevalence of latent tuberculosis infection and feasibility of TB preventive therapy among Thai prisoners: a cross-sectional study , 2021, BMC Public Health.

[3]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[4]  J. Andrews,et al.  Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis , 2021, The Lancet. Public health.

[5]  P. Rodari,et al.  Tuberculosis and pharmacological interactions: A narrative review , 2020, Current research in pharmacology and drug discovery.

[6]  A. Giacomelli,et al.  Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view , 2020, Tuberculosis.

[7]  M. Faccini,et al.  Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study , 2020, European Respiratory Journal.

[8]  Gibril J. Njie,et al.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  A. Benedetti,et al.  Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. , 2019, The Lancet. Infectious diseases.

[10]  D. Holland,et al.  Using Directly Observed Therapy (DOT) for latent tuberculosis treatment – A hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA , 2019, PloS one.

[11]  J. Mohle-Boetani,et al.  Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014 , 2019, Public health reports.

[12]  S. Bur,et al.  High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons , 2019, Journal of public health management and practice : JPHMP.

[13]  S. Basu,et al.  Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil , 2019, PLoS medicine.

[14]  A. Ohkado,et al.  A situational analysis of latent tuberculosis infection among incarcerated population in Japan , 2018, PloS one.

[15]  T. Chorba,et al.  High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Chaisson,et al.  Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  M. Mohraz,et al.  Adherence to Antiretroviral Therapy and Tuberculosis Treatment in a Prison of Tehran, Iran. , 2016, Infectious disorders drug targets.

[18]  M. G. B. Ceccato,et al.  Prevalence of latent Mycobacterium tuberculosis infection in prisoners , 2016, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[19]  D. Murray,et al.  Can Social History Variables Predict Prison Inmates' Risk for Latent Tuberculosis Infection? , 2012, Tuberculosis research and treatment.

[20]  Truls Østbye,et al.  Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study , 2012, BMC Public Health.

[21]  J. Spetz,et al.  Isoniazid vs. Rifampin for Latent Tuberculosis Infection in Jail Inmates , 2012, Journal of correctional health care : the official journal of the National Commission on Correctional Health Care.

[22]  P. Shao,et al.  Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  P. Brickner,et al.  Latent Tuberculosis and Active Tuberculosis Disease Rates among the Homeless, New York, New York, USA, 1992–2006 , 2009, Emerging infectious diseases.

[24]  M. Lashley.  A targeted testing program for tuberculosis control and prevention among Baltimore city's homeless population. , 2007, Public health nursing.

[25]  L. Kawamura,et al.  Incidence of TB in inmates with latent TB infection: 5-year follow-up. , 2005, American journal of preventive medicine.

[26]  C. Chee,et al.  Contact screening and latent TB infection treatment in Singapore correctional facilities. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[27]  R. Reves,et al.  Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. , 2005, Chest.

[28]  T. Conklin,et al.  Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  T. Sterling,et al.  Evaluation of an extensive tuberculosis contact investigation in an urban community and jail. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[30]  Audrey A Reichard,et al.  Assessment of tuberculosis screening and management practices of large jail systems. , 2003, Public health reports.

[31]  M. Lobato,et al.  Treatment for latent TB in correctional facilities: a challenge for TB elimination. , 2003, American journal of preventive medicine.

[32]  C. Hamilton,et al.  Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[33]  R. Reves,et al.  Skin-Test Screening and Tuberculosis Transmission among the Homeless , 2002, Emerging infectious diseases.

[34]  J. Tapia,et al.  Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. , 2001, Chest.